Skip to main content

Main utility

  • Browse negotiations
  • Careers
  • Contact us
  • News
Français FR
Home Home

Main navigation

  • Inside the pCPA
    • Our purpose
      • Our vision and strategy
      • What we do
    • Our people
      • Governance
      • Members
      • Who we are
  • Insights and updates
    • Our public reimbursement system
      • Drugs we negotiate
      • Our role in the drug reimbursement system
      • Glossary
    • Our updates
      • News
      • Recent negotiation activity
    • Our impact
      • Performance dashboard
      • Reports
  • Negotiations
    • Negotiation activity
      • Browse negotiations
      • Recent negotiation activity
    • Drug categories
      • Brand-name drugs
      • Biosimilar drugs
      • Generic drugs
    • Processes and frameworks
      • Standard negotiation process
      • Expedited negotiation pathways
      • Early negotiation process
      • Targeted negotiation process
      • Temporary access process
      • Biosimilar drug review process
      • Tiered pricing framework
      • Centralized price change process
Français FR

Main navigation

  • Inside the pCPA
    • Our purpose
      • Our vision and strategy
      • What we do
    • Our people
      • Governance
      • Members
      • Who we are
  • Insights and updates
    • Our public reimbursement system
      • Drugs we negotiate
      • Our role in the drug reimbursement system
      • Glossary
    • Our updates
      • News
      • Recent negotiation activity
    • Our impact
      • Performance dashboard
      • Reports
  • Negotiations
    • Negotiation activity
      • Browse negotiations
      • Recent negotiation activity
    • Drug categories
      • Brand-name drugs
      • Biosimilar drugs
      • Generic drugs
    • Processes and frameworks
      • Standard negotiation process
      • Expedited negotiation pathways
      • Early negotiation process
      • Targeted negotiation process
      • Temporary access process
      • Biosimilar drug review process
      • Tiered pricing framework
      • Centralized price change process

Main utility

  • Browse negotiations
  • Careers
  • Contact us
  • News
  • Home /
  • Listing 3 - Actual negotiations

Listing 3 - Actual negotiations

Search by drug, manufacturer, or indication

Displaying 121 - 130 of 1165

Okedi (risperidone)

Status:

Concluded with an LOI

Manufacturer:

Bausch Health, Canada Inc.

Indication:

Schizophrenia in Adults

Last updated May 25, 2026

Quillivant ER (Methylphenidate Hydrochloride)

Status:

Active negotiation

Manufacturer:

KYE Pharmaceuticals Inc.

Indication:

Attention-deficit/hyperactivity disorder (ADHD)

Last updated May 21, 2026

Scemblix (asciminib)

Status:

Concluded with an LOI

Manufacturer:

Novartis Pharmaceuticals Canada Inc.

Indication:

Adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase

Last updated May 20, 2026

Opzelura (ruxolitinib)

Status:

Concluded without agreement

Manufacturer:

Incyte Biosciences Canada Corporation

Indication:

Atopic dermatitis

Last updated May 20, 2026

Elahere (mirvetuximab soravtansine)

Status:

Concluded without agreement

Manufacturer:

AbbVie Corporation

Indication:

For the treatment of adult patients with folate receptor-alpha (FRα) positive*, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.

Last updated May 14, 2026

TBD (denosumab)

Status:

Negotiations were not pursued

Manufacturer:

Sun Pharma Canada Inc.

Indication:

Multiple Indications

Last updated May 6, 2026

Yondelis (trabectedin)

Status:

Active negotiation

Manufacturer:

Xediton Pharmaceuticals Inc.

Indication:

In combination with doxorubicin as first-line treatment for advanced unresectable or metastatic uterine or soft tissue leiomyosarcoma

Last updated April 29, 2026

Imfinzi (durvalumab)

Status:

Concluded with an LOI

Manufacturer:

AstraZeneca Canada Inc.

Indication:

In combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, followed by adjuvant durvalumab monotherapy, for the treatment of adult patients with resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).

Last updated April 29, 2026

Vanflyta (quizartinib)

Status:

Concluded with an LOI

Manufacturer:

Daiichi Sankyo Pharma Canada

Indication:

In combination with standard cytarabineand anthracycline induction and standard cytarabine consolidationchemotherapy, and as continuation maintenance monotherapy followingconsolidation, for the treatment of adult patients with newly diagnosed acutemyeloid leukemia (AML) that is FMS-like tyrosine kinase 3 internal tandemduplication (FLT3-ITD) positive.

Last updated April 29, 2026

Loqtorzi (toripalimab)

Status:

Negotiations were not pursued

Manufacturer:

Apotex Inc.

Indication:

For the treatment of adults with recurrent unresectable or metastatic nasopharyngeal carcinoma (NPC) with disease progression on or after a platinum-containing chemotherapy

Last updated April 27, 2026

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 11
  • Page 12
  • Current page 13
  • Page 14
  • Page 15
  • …
  • Next page Next ›
  • Last page Last »

Page updated: February 12, 2026

Our team is located across the country, on the ancestral and unceded territories of Canada’s Indigenous Peoples. We recognize their inherent and treaty rights, and we’re grateful to stand, live, and work on these lands.

pan-Canadian Pharmaceutical Association

General inquiries: Email us

Footer Navigation

  • Inside the pCPA
    • Who we are
    • What we do
    • Our vision and strategy
    • Governance
    • Members
  • Insights and updates
    • Our role
    • Drugs we negotiate
    • Performance dashboard
    • News
    • Glossary
  • Negotiations
    • Recent negotiation activity
    • Standard negotiations
    • Expedited pathways
    • Biosimilar drugs
    • Brand-name drugs
    • Generic Drugs

Footer secondary

  • Browse negotiations
  • Careers
  • Contact us
  • News

Copyright © 2026 pan-Canadian Pharmaceutical Alliance. All rights reserved.

Footer Utility

  • Privacy Policy
  • Terms of use